ClinicalTrials.Veeva

Menu

A Long-term Observational Study to Describe the Use of Vitamin-C Injektopas® 7.5 g in Patients With Vitamin C Deficiency

P

Pascoe Natural Healthcare

Status

Enrolling

Conditions

Chronic Disease
Acute Disease
Deficiency, Vitamin C

Study type

Observational

Funder types

Industry

Identifiers

NCT06983847
214A18VCAT

Details and patient eligibility

About

The goal of this observational study is to learn more about the disease and the symptoms where the product will use and in which patient groups. Further on, it is interesting to know clinical pictures, the symptoms improve. Patients with acute or chronical disease with vitamin c deficiency could be involved.

The main questions it aims to answer are:

  • how do the symptoms of the disease change
  • how is the tolerability

Full description

The aim of this long-term observational study is to document the use of Vitamin C Injektopas® 7.5g in patients with vitamin C deficiency. The deficiency condition can be diagnosed either by laboratory diagnosis or clinically, i.e. symptomatically on the basis of general vitamin C deficiency symptoms (e.g. weakness, fatigue, susceptibility to infections and psychological complaints such as depressive moods) through to more specific deficiency symptoms, which are primarily related to impaired collagen formation and therefore primarily affect connective tissue, blood vessels, cartilage and bones. These include, above all, haemorrhages in the skin, inflamed and bleeding gums - through to tooth loss, joint effusions, pain in the joints, bones and muscles as well as poorly healing wounds, etc.

The survey should be used to assess the disease underlying the vitamin C deficiency (the so-called underlying disease), the reduction in the symptoms of the disease under therapy and also the tolerability. Both acute and chronic underlying diseases should be taken into account.

In addition to the symptom enquiry, the global assessment of the efficacy and tolerability of therapy with Vitamin C Injektopas® 7.5g is evaluated.

Enrollment

1,000 estimated patients

Sex

All

Ages

18 to 120 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with vitamin C deficiency
  • Age ≥ 18 years

Exclusion criteria

  • Hypersensitivity to the active ingredient or any of the excipients
  • Oxalate urolithiasis
  • Iron storage disease (thalassemia, hemochromatosis, sideroblastic anemia) or recent red blood cell transfusion
  • Renal insufficiency
  • Glucose-6-phosphate dehydrogenase deficiency/defect
  • Pregnant/breastfeeding women

Trial design

1,000 participants in 2 patient groups

Vit C deficiency in acute diseases
Description:
Patients with vitamin C deficiency due to a acute underlying disease treated with Vitamin-C injektopas® 7.5 g
Vit C deficiency in chronic diseases
Description:
Patients with vitamin C deficiency due to a chronic underlying disease treated with Vitamin-C injektopas® 7.5 g

Trial contacts and locations

1

Loading...

Central trial contact

Bianka B. Krick, CRA; Jennifer Brueckmann, CRA

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems